SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicines’ prices should not escalate: SC

18 Nov 2011 Evaluate

Concerned over rise in prices of medicines, the Supreme Court has tasked central government to ensure that the prices remain at same level post introduction of the proposed Pharma Pricing Policy, 2011. 'Prices should not escalate. There are apprehensions that prices will escalate. In the name of the new policy the prices shall not escalate. Because we have much more consumers in India than other parts of the world,' the court observed.

On January 17, a bench of justices G S Singhvi and S D Mukhopadhyaya posted the matter for further hearing. The Additional Solicitor General Parag Tripathi said that the notification of the new policy would take place only after the Group of Ministers (GoM) takes a decision in about three months time.

The issue came up for hearing during a PIL filed in 2003 by the All India Drugs Action Network and others which had complained that presently around 78 drugs are placed under the Drugs (Prices Control) Order, 1995 (DPCO) making rest of the medicines beyond the reach of common man.

In an affidavit, the Department of Chemicals and Petrochemicals, however, informed court that it had initiated action for formulating a new policy, in which “348 medicines including in the National List of Essential Medicines (NLEM), 2011 and associated medicines will be brought under price control.”

As per the Department of Chemicals and Petrochemicals, a draft National Pharmaceutical Pricing Policy 2011 (NPPP-2011) has been circulated among all the stake holders and ministries concerned besides being put on its official website for comments. However, senior counsel Colin Gonzalves representing NGO informed bench that the proposed drug policy was fraught with apprehension of a steep hike and wanted the court to restrain the authorities from taking any step.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×